Switching From Ozempic to Mounjaro After a Semaglutide Plateau

Mounjaro starts everyone at 2.5 mg a week, so switching from Ozempic to Mounjaro after a plateau means going back to a starting dose (Mounjaro label, section 2.1). In a 6-month chart review, people who switched after a stall lost a further 8.1%, and people who had lost under 5% on semaglutide lost 2.9% (Barenbaum et al., 2026).

Key facts

• No label gives a conversion from semaglutide to tirzepatide, and each tirzepatide label has one starting dose for everyone (Zepbound label, section 2.1).
• Start the new weekly drug 7 days after the last dose of the old one, with no overlap (Whitley et al., 2023; Zepbound label, section 1).
• You reach 10 mg, the lower SURMOUNT-5 tirzepatide dose, in week 13 at the earliest, and 15 mg in week 21 (Zepbound label, section 2.1).
• On oral contraceptives, change to a non-oral method, or add a barrier one, for 4 weeks after starting tirzepatide and after each dose increase (Zepbound label, section 8.3).
• US Mounjaro is licensed for type 2 diabetes, so tirzepatide for weight means Zepbound (Mounjaro label, section 1); UK Mounjaro covers weight too (UK label, 4.1).

What happens when people switch at a plateau

A 2026 chart review from Weill Cornell Medicine in New York followed adults who started tirzepatide between May 2022 and January 2023, and compared their weight 6 months later (Barenbaum et al., 2026). Of them, 61 had switched from semaglutide, taken at 1.7 mg a week or more, after a stall or a poor response. How much more they lost depended on which it was.

Among all 293 people in the review, those who had already lost 10% or more before tirzepatide lost 7.2% on it, against 10.3% for everyone else (Barenbaum et al., 2026). The review had no comparison group that stayed on semaglutide.

Is Mounjaro better than Ozempic for weight loss?

Tirzepatide took off more weight than semaglutide in SURPASS-2 and SURMOUNT-5, which compared the two drugs head to head. Both enrolled people who were starting one of the two drugs, so neither measured a switch after a stall. SURPASS-2 followed 1,879 adults with type 2 diabetes for 40 weeks (Frías et al., NEJM 2021). SURMOUNT-5 followed 751 adults with obesity and without diabetes for 72 weeks (Aronne et al., NEJM 2025).

SURPASS-2 is the closer match for Ozempic users, because its semaglutide arm took 1 mg, an Ozempic dose. SURMOUNT-5 used the Wegovy doses, and its top dose of 2.4 mg is above Ozempic’s 2 mg ceiling (Ozempic label, section 2.2). Both trials were open-label, so participants knew which drug they were taking.

In SURMOUNT-5, waist size fell 18.4 cm on tirzepatide against 13.0 cm on semaglutide (Aronne et al., NEJM 2025). Whether the extra loss costs more muscle depends on the lean share of each drug’s loss, which scan studies of Zepbound and Wegovy measured separately.

How the restart works

Zepbound or Mounjaro, and the first dose

Tirzepatide is sold in the US as Zepbound, licensed for weight reduction, and as Mounjaro, licensed for type 2 diabetes (Zepbound label, section 1; Mounjaro label, section 1). In the UK, Mounjaro’s Summary of Product Characteristics (SmPC), the prescribing document, also lists weight management, from a BMI of 30, or 27 with a weight-related condition (Mounjaro SmPC, section 4.1).

Zepbound and the UK Mounjaro SmPC hold 2.5 mg for 4 weeks and then move to 5 mg (Zepbound label, section 2.1; Mounjaro SmPC, section 4.2). The US Mounjaro label also starts at 2.5 mg, then raises the dose in 2.5 mg steps only if more glucose control is needed (Mounjaro label, section 2.1). None of them offers a conversion, so a move from semaglutide to tirzepatide begins on the first step whatever dose you left behind.

Tirzepatide acts on GIP and GLP‑1 receptors, semaglutide on the GLP‑1 receptor alone (Zepbound label, section 1; Wegovy label, section 1). Their dose ladders also start and step at different doses.

When to take the first shot

Take the first tirzepatide shot 7 days after your last weekly Ozempic dose, the gap a 2023 Clinical Diabetes report on GLP‑1 shortages advises when moving between weekly drugs (Whitley et al., 2023). The Zepbound label advises against taking tirzepatide alongside any GLP‑1 receptor agonist, Ozempic included (Zepbound label, section 1).

Semaglutide stays in the blood for about 5 weeks after a last Ozempic dose (Ozempic label, section 12.3). After a last Wegovy dose of 2.4 or 7.2 mg, it stays for about 5 to 7 weeks (Wegovy label, section 12.3).

How long it takes to reach 10 or 15 mg

With at least 4 weeks on each Zepbound dose step, the fourth step, 10 mg, cannot start before week 13, and the top dose of 15 mg not before week 21 (Zepbound label, section 2.1).

Say your last Ozempic dose is on Monday, October 5, 2026. With the 7-day gap, the first 2.5 mg dose falls on Monday, October 12. On the earliest schedule, 5 mg follows on November 9, 10 mg on January 4, 2027, and 15 mg on March 1, 2027. Enter your own first 2.5 mg day in the dose titration planner to get your dates.

Side effects and contraception

Restarting at 2.5 mg means going through the dose steps again. In the Zepbound weight trials, nausea affected 25 to 29% of people on 5 to 15 mg, against 8% on placebo (Zepbound label, section 6.1). Most nausea, vomiting and diarrhea came during dose escalation and eased over time.

The Zepbound label warns that tirzepatide "may reduce the efficacy of oral hormonal contraceptives due to delayed gastric emptying" (Zepbound label, section 8.3). It advises switching to a non-oral method, or adding a barrier method, for 4 weeks after the first dose and again after every dose increase.

The UK SmPC gives the same advice (Mounjaro SmPC, section 4.5). The Ozempic and Wegovy labels have no such instruction, so this step is new when you switch.

Before you switch

A new drug does nothing about late doses or a compounded vial that changed strength, so run the checks to do before changing drugs first. Ozempic’s highest dose is 2 mg a week (Ozempic label, section 2.2). If you are on Wegovy, the US label allows 7.2 mg once 2.4 mg has been tolerated for at least 4 weeks and more weight loss is needed (Wegovy label, section 2.2).

What to bring when you ask about a switch

Bring the date your weight stopped falling, how much you had lost before the stall as a percentage of your starting weight, and the date of your last semaglutide dose. The percentage places you in one of the chart review’s groups, which split at 5%. The last-dose date sets the earliest day for your first tirzepatide shot.

That last-dose date, and later your first 2.5 mg day and each step after it, are on hand when every shot is logged in Pensday with its date and dose.